Get started
Author

Ritesh R. Kotecha

Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
2019 · Lynda Vuong, Ritesh R. Kotecha, et al. · Cancer Discovery · 436
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence
2016 · Ritesh Kotecha, Akiyoshi Takami, et al. · Oncotarget · 396
PDF
Towards individualized therapy for metastatic renal cell carcinoma
2019 · Ritesh R. Kotecha, Robert J. Motzer, et al. · Nature Reviews Clinical Oncology · 235
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates
2022 · Chung-Han Lee, Martin H. Voss, et al. · Journal of Clinical Oncology · 204
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
2016 · Mattias Carlsten, Neha Korde, et al. · Clinical Cancer Research · 166
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
2019 · A.Y. Shah, R.R. Kotecha, et al. · European Journal of Cancer · 119
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma
2021 · Jack P. Gleeson, Ines Nikolovski, et al. · Clinical Cancer Research · 87
Interventions to Improve Oral Chemotherapy Safety and Quality
2017 · Jessica A. Zerillo, Benjamin A. Goldenberg, et al. · JAMA Oncology · 86
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
2022 · Ramin Sedaghat Herati, David A. Knorr, et al. · Nature Immunology · 83
PDF
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
2022 · Maria I. Carlo, Kyrollis Attalla, et al. · European Urology · 68
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression
2020 · Julian Marcon, Renzo G. DiNatale, et al. · Clinical Cancer Research · 53
Deciphering radiological stable disease to immune checkpoint inhibitors
2022 · J. Luo, S. Wu, et al. · Annals of Oncology · 51
Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape
2022 · Mahdi Golkaram, Fengshen Kuo, et al. · Genome Medicine · 50
PDF
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
2020 · Yasser Ged, Joshua L Chaim, et al. · Journal for ImmunoTherapy of Cancer · 50
Unbiased Pathogen Detection and Host Gene Profiling for Conjunctivitis
2019 · Prajna Lalitha, Gerami D. Seitzman, et al. · Ophthalmology · 42
Are Wet-Induced Wrinkled Fingers Primate Rain Treads?
2011 · Mark Changizi, Romann Weber, et al. · Brain Behavior and Evolution · 39
PDF
Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)
2023 · Samer Srour, Ritesh Kotecha, et al. · Cancer Research · 38
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
2022 · Yasser Ged, Alejandro Sanchez, et al. · Clinical Cancer Research · 38
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing
2021 · Hong Truong, Rania Sheikh, et al. · European Urology Oncology · 38
Trigeminal Neuralgia Treated With Stereotactic Radiosurgery: The Effect of Dose Escalation on Pain Control and Treatment Outcomes
2016 · Rupesh Kotecha, Ritesh Kotecha, et al. · International Journal of Radiation Oncology*Biology*Physics · 37
Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
2024 · Kelly N. Fitzgerald, Chung-Han Lee, et al. · European Urology · 36
PDF
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
2021 · Chung-Han Lee, Martin H Voss, et al. · Journal of Clinical Oncology · 32
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
2021 · Chung-Han Lee, Renzo G. DiNatale, et al. · Molecular Cancer Research · 31
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma
2021 · Ritesh R. Kotecha, Ronan Flippot, et al. · Journal of the National Comprehensive Cancer Network · 31
PDF
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
2022 · Angela Yoo, Cerise Tang, et al. · European Urology Focus · 27
Works count: 245
Citation count: 2,958
H-index: 26
I10-index: 43
Year
Topic
Type